Ciclosporin: 9 agencies, 2013–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) has been harder on ciclosporin than on its own caseload: it refused 4 of 6 decisive submissions here (67%), against a base rate of 11% across everything it has assessed.
The file has been open for more than a decade: 12.6 years separate the first record, 17 Dec 2013 at CONITEC (Brazil), from the most recent, 2026 at PBAC (Australia).
CIPM (Spain) changed its position: not recommended on 7 Apr 2021, recommended by 29 Jan 2025, after a resubmission.
No assessment is on file from G-BA (Germany), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for ciclosporin, 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 5 of 23 records date from 2023 or later.
7 distinct indication wordings are recorded for ciclosporin by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 23 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
CONITEC (Brazil) was first to assess ciclosporin, on 17 Dec 2013; PBAC (Australia) did not open a file until 2021 — a wide spread of 7.6 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 11 years in total.
7 of the 9 agencies here assessed ciclosporin more than once, HAS (France) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for ciclosporin.
The full ledger for ciclosporin reads 11 recommended, 5 not recommended, 3 restricted and 2 withdrawn, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| TLV (Sweden) | 28 Apr 2026 | Vevizye ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| HAS (France) | 31 Aug 2022 | Listing (Transparency Committee) | SMR insufficient | source |
| PBAC (Australia) | 2022 | Chronic severe dry eye disease with keratitis | Recommended | source |
| CIPM (Spain) | 7 Apr 2021 | Indicación terapéutica autorizada: Tratamiento de la queratoconjuntivitis vernal (VKC, por sus siglas en inglés) grave e… | not financed by the SNS (financed 2025-01) | source |
| SMC (Scotland) | 10 Dec 2018 | treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents (until the age of 18) | accepted | source |
18 further decisions for ciclosporin, across 9 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 12 further source documents.
Related molecules
- pegcetacoplan — same ATC class S01X — Ophthalmologicals
- mercaptamine — same ATC class S01X — Ophthalmologicals
- voretigene neparvovec — same ATC class S01X — Ophthalmologicals
- ocriplasmin — same ATC class S01X — Ophthalmologicals
- cenegermin — same ATC class S01X — Ophthalmologicals
- insulin glargine — also decided by TLV in 2026Q2
Coverage: 23 decisions for ciclosporin from 9 agencies, 2013 to 2026. Data to 7 Sep 2026. ATC class S01X — Ophthalmologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.